NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th

Rhea-AI Summary

NRx Pharmaceuticals (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, and its wholly-owned subsidiary HOPE Therapeutics, announced their participation in H.C. Wainwright's 27th Annual Global Investment Conference.

The company's Chairman and CEO, Dr. Jonathan Javitt, will engage in a fireside chat on September 8, 2025, from 4:30 to 5:00 PM ET. The presentation will be available via webcast on the company's investor relations website, with a replay accessible for 30 days after the event.

Management will also be conducting one-on-one meetings with investors during the conference.

WILMINGTON, Del., Sept. 03, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, today announced that Jonathan Javitt, M.D., M.P.H., Chairman and Chief Executive Officer of NRx Pharmaceuticals, will participate in a fireside chat at H.C. Wainwright’s 27th Annual Global Investment Conference on Monday, September 8, 2025, from 4:30 to 5:00 PM ET.

A webcast of the fireside chat will be available on the Events page of the Investors section of the Company’s website at https://ir.nrxpharma.com/events. A replay of the webcast will be available two hours after the event and will be accessible for 30 days following the event.

Management will also be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the NRx Pharmaceuticals management team should contact their H.C. Wainwright representative or Brian Korb at astr Partners, brian.korb@astrpartners.com.

About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression.

About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a healthcare delivery company, which plans to build a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new
information, future events or otherwise.

For further information: Matthew Duffy                                                                         Co-CEO, Hope Therapeutics, Inc.                                           Chief Business Officer, NRx Pharmaceuticals, Inc.               mduffy@nrxpharma.com

Brian Korb Managing Partner, astr partners (917) 653-5122 brian.korb@astrpartners.com

FAQ

When is NRx Pharmaceuticals (NRXP) presenting at the H.C. Wainwright Conference?

NRx Pharmaceuticals will present on Monday, September 8, 2025, from 4:30 to 5:00 PM ET in a fireside chat format.

How can investors access the NRXP fireside chat presentation?

The presentation will be available via webcast on the Events page of NRx Pharmaceuticals' investor relations website at https://ir.nrxpharma.com/events.

How long will the NRXP presentation replay be available?

The webcast replay will be available two hours after the event and remain accessible for 30 days following the presentation.

How can investors schedule one-on-one meetings with NRXP management?

Investors can schedule meetings by contacting their H.C. Wainwright representative or reaching out to Brian Korb at astr Partners via email at brian.korb@astrpartners.com.